GP2013 in the Treatment of Patients With Previously Untreated, Advanced Stage Follicular Lymphoma (ASSIST_FL)

To Evaluate the Complete Response (CR) Rate During the Combination Treatment Period

Time frame: 24 weeks

To Evaluate the Partial Response (PR) Rate During the Combination Treatment Period

Time frame: 24 weeks

To Evaluate the Progression Free Survival (PFS) With up to 3 Years of Follow-up Post Randomization

Number of participants with progression free survival events

Time frame: 3 years

To Evaluate the Overall Survival (OS) With up to 3 Years of Follow-up Post Randomization, as Assessed by the Number of Deaths

OS was defined as the time from date of randomization to date of death due to any cause. If a patient was not known to have died, OS was censored at the date of last contact including survival follow-up.

Time frame: 3 years

To Evaluate the Incidence of Immunogenicity (ADA Formation) Against GP2013 and MabThera (Rituximab)

number of participants with confirmed positive ADA

Time frame: 24 weeks, 3 years

To Evaluate a PK Marker Following the Treatment With GP2013-Chemotherapy and MabThera-Chemotherapy (C Max)

C max For descriptive purposes only, no hypothesis testing

Time frame: day 63